{"input_url":"https://www.ajmc.com/view/fda-advisory-panel-weighs-access-to-7-popular-peptides-this-week","gnews_decode":"https://www.ajmc.com/view/fda-advisory-panel-weighs-access-to-7-popular-peptides-this-week","http_status":200,"final_url":"https://www.ajmc.com/view/fda-advisory-panel-weighs-access-to-7-popular-peptides-this-week","html_length":486662,"trafilatura_result":"ok","text_length":537,"text_preview":"The FDA's Pharmacy Compounding Advisory Committee (PCAC) is meeting July 23-24 to evaluate whether 7 popular but unapproved peptides should be added to the agency's 503A Bulks List, a designation that, if finalized by FDA through rulemaking, would permit eligible state-licensed 503A compounding phar","verdict":"OK"}